Literature DB >> 20209595

Acute and long-term effects of inhaled iloprost in portopulmonary hypertension.

Maria Teresa Melgosa1, Giovanni L Ricci, Juan Carlos García-Pagan, Isabel Blanco, Pilar Escribano, Juan G Abraldes, Josep Roca, Jaume Bosch, Joan Albert Barberà.   

Abstract

Portopulmonary hypertension (PoPH) is a serious condition without an established treatment. Drugs used to treat pulmonary hypertension may have detrimental effects on portal hypertension. This study was designed to assess in patients with PoPH the acute effects of inhaled iloprost (iILO) on pulmonary and hepatic hemodynamics and to evaluate the clinical outcome after 12 months of treatment. We conducted 2 separate studies. In the first one, 21 patients with PoPH were acutely tested with 2.8 microg of iILO. Pulmonary and hepatic hemodynamics were assessed at the baseline and through 60 minutes after iILO. In the second one, we retrospectively evaluated 12 patients treated with iILO (30 microg/day) for more than 1 year. The 6-minute walk distance (6MWD), functional class (FC), and echocardiogram were analyzed at the baseline and after 12 months of treatment. In the acute study, iILO rapidly reduced pulmonary artery pressure (PAP; -16% + or - 8%, P < 0.001) and pulmonary vascular resistance (-18% + or - 14%, P < 0.001). The cardiac output did not change initially but decreased after 30 minutes. The hepatic venous pressure gradient (HVPG) and hepatic blood flow did not vary through the study. Pulmonary vasodilation induced by iILO was inversely related to HVPG. In the long-term evaluation, iILO improved FC by 1 or more in 7 patients (P = 0.04) and increased 6MWD by 67 + or - 59 m at 12 months (P < 0.001). No change in systolic PAP was observed. Two patients died because of hepatic complications, and 4 additional patients presented clinically significant events that were related to hepatic disease in 2 and worsening of pulmonary hypertension in 2. We conclude that in patients with PoPH, iILO produces rapid and selective pulmonary vasodilation without altering the hepatic hemodynamics. Its long-term use may provide sustained improvements in symptoms and exercise tolerance in some patients with PoPH. A randomized, controlled trial is warranted to establish its clinical role in this serious condition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20209595     DOI: 10.1002/lt.21997

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  13 in total

1.  What do we take consideration in the patient who has an unpredicted severe portopulmonary hypertension in liver transplantation?: a case report.

Authors:  HyunJung Koh; Seulgi Ahn; Jaemin Lee
Journal:  Korean J Anesthesiol       Date:  2015-01-28

Review 2.  Inhaled pulmonary vasodilators: a narrative review.

Authors:  Kai Liu; Huan Wang; Shen-Ji Yu; Guo-Wei Tu; Zhe Luo
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  Portopulmonary hypertension and hepatopulmonary syndrome.

Authors:  Florence Aldenkortt; Marc Aldenkortt; Laurence Caviezel; Jean Luc Waeber; Anne Weber; Eduardo Schiffer
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

Review 4.  Role of cardiovascular intervention as a bridge to liver transplantation.

Authors:  Zankhana Raval; Matthew E Harinstein; James D Flaherty
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 5.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

Review 6.  Portopulmonary hypertension in liver transplant candidates.

Authors:  Serife Savas Bozbas; Huseyin Bozbas
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 7.  Schistosomiasis-associated pulmonary hypertension.

Authors:  Demosthenes G Papamatheakis; Ana Olga H Mocumbi; Nick H Kim; Jess Mandel
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

8.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

Review 9.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

Review 10.  Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.

Authors:  Lynn A Fussner; Michael J Krowka
Journal:  Curr Gastroenterol Rep       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.